References
- Angst J. Epidemiology of depression. In:Depression. Neurobiological, psychopathological and therapeutic advances. Honig A, Van Praag HM (Eds), Wiley, Chichester, UK, 17–30 (1997).
- Cassem EH. Depressive disorders in the medically ill: an overview. Rychosomatics 36, S2—S10 (1995).
- American Psychiatric Association. Diagnostic and Statistical Manual of mental Disorders (4th Edition). American Psychiatric Association, Washington, DC, USA (1994).
- Mendlewicz J, Sevy S, Mendlebaum K. Molecular genetics in affective illness. Life Sci. 52,231–242 (1993).
- Berrettini WH. Genetics of psychiatric disease. Ann. Rev Med. 51,465–479 (2000).
- •Concise overview about the genetic background of psychiatric disorders, including depression.
- Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J. Psychiatry 122,509–522 (1965).
- •Classic paper proposing the serotonin and noradrenaline hypotheses of depression.
- Coppen AJ. The biochemistry of affective disorders. Br. Psychiatry 113,1237–1264 (1967).
- Maes M, Meltzer HYM. The serotonin hypothesis of major depression: A review. Rev Neurosci. 4,407–416 (1995).
- Charles G. DST non-normalization, clinical recovery and symtpomatic relapse. In:Biological markers of depression: State of the art. Ansseau M, Von Frenckell R, Fank G (Eds), Excerpta Medica, Amsterdam, The Netherlands, 33–36 (1991).
- Holsboer E Neuroendocrinology and mood disorders. In: Psychopharmacology: The fourth generation in progmss. Bloom FE, Kupfer DJ (Eds) Raven, New York, USA, 957–969 (1995).
- Maes M. The immune pathophysiology of major depression. In: Depression. Neurobiological, psychopathological and therapeutic advances. Honig A, Van Praag HM (Eds), Wiley, Chichester, UK, 197–216 (1997).
- Seligman MEE Learned helplessness. Freeman, San Francisco, USA (1975).
- •Classic paper introducing an important animal model for depression.
- Beck AT The past and future of cognitive therapy. J. PTchother. Pract. Res. 6,276–284 (1997).
- Brown GW, Harris TO, Hepworth C. Life- events and endogenous depression. Arrh. Gen. Psychiatry 51,525–534 (1994).
- Derix MMA, Jolles J. Neuropsychological abnormalities in depression: Relation between brain and behaviour. In: Depression. Neurobiological, psychopathological and therapeutic advances. Honig A, Van Praag HM (Eds), Wiley, Chichester, UK, 109–126 (1997).
- Kent JM. SNaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet355, 911–918 (2000).
- •Good review of modem postSSRF antidepressants.
- Dunner DL. Acute and maintenance treatment of chronic depression. J. Clin. Psychiatry62\(Suppl. 6), 10–16 (2001).
- Wong ML, Licinio J. Research and treatment approaches to depression/Vat. Rev Neurosci. 2,343–351 (2001).
- Duman RS. Novel therapeutic approaches beyond the 5-HT receptor. Biol. Psychiatry 44,324–335 (1998).
- Montminy MR, Gonzalez GA, Yamamoto KK. Regulation of cAMP-inducible genes by CREB. Trends Neurosci. 13,184–188 (1990).
- •Review giving an overview about the principles of cAMP signaling and induction of the transcription factor CREB.
- Meyer TE, Habener JE Cyclic adenosine, 5'-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocr Rev 14, 269–290 (1993).
- Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54,597–606 (1997).
- •Important paper proposing a molecular hypothesis of affective disorders beyond the transmitter—receptor interaction.
- Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol. PTchiatry46,1181–1191 (1999).
- Ghosh A, Greenberg ME. Calcium signaling in neurons: Molecular mechanisms and cellular consequences. Science 268,239–247 (1995).
- Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 95,725–748 (1995).
- Manganiello VC, Murata T, Taira et al Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys. 95,1–13 (1995).
- Dowlatshahi D, MacQueen GM, Wang JF et al G Protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide and treatment at the time of death. I Neurochem. 73,1121–1126 (1999).
- •Post mortem study supporting the theory of an altered cAMP signaling in mood disorders.
- Manji HK, Moore GJ, Rajkowska G et al. Neuroplasticity and cellular resilience in mood disorders. Mal Bychiatry5, 578–593 (2000).
- Perez J, Tardito D, Mori S et al Abnormalities of cAMP signaling in affective disorders: implication for pathophysiology and treatment. Bipolar Disoml 2,27–36(2000).
- Vaidya VA, Duman RS. Depresssion. Emerging insights from neurobiology. BE Med. Bull. 57,61–79 (2001).
- Sapolsky RM. Stress, glucocorticoids and damage to the nervous system: The current state of confusion. Stress 1,1–19 (1996).
- Sheline YI, Wany P, Gado MET et al Hippocampal atrophy in recurrent major depression. Proc. Natl Acad. Sri. USA 93, 3908–3913 (1996).
- Rothschild AJ, Samson JA, Bond TC et al Hypothalamic—pituitary—adrenal axis activity and 1-year outcome in depression. Biol. PTchiatry34, 392–400 (1993).
- Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Mal Psychiatry 1,336–342 (1996).
- Young EA, Vazquez D. Hypercortisolemia, hippocampal glucocorticoid receptors and fast feedback. Mal Psychiatry 1,149–159 (1996).
- Nestler EJ. Antidepressant treatments in the 21st century. Biol. PTchiatry44, 526–533 (1998).
- Smith MA, Makino S, Kvetnansky R et al. Stress alters the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. j Neurosci. 15,1768–1777 (1995).
- Gould E, Tanapat P, McEwen BS et al Proliferation of granule cell precursors in the dentate gyrus of adult monkey is diminished by stress. Proc. Natl Acad. Sci. USA 95,3168–3171 (1998).
- •Original paper demonstrating the influence of stress on neurogenesis in primates.
- Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl Acad. Sc]. USA 95,13290–13295 (1998).
- Bremner JD, Narayan M, Anderson ER et al Hippocampal volume reduction in major depression. Am J: PFchiatry157, 115–118 (2000).
- Duman RS, Malberg J, Nakagawa S et al. Neuronal plasticity and survival in mood disorders. Biol. Psychiab y 48, 732–739 (2000).
- Sapolsky RM. Atrophy of the hippocampus in posttraumatic stress disorder: how and when? klippocampusll, 90–91 (2001).
- Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Pmg. Brain. Res. 126,413–431 (2000).
- Thome J, Pesold B, Baader M et al Stress differentially regulates synaptophysin and synaptotagmin expression in hippocampus. PTchiati y50, 809–812 (2001).
- Dwivedi Y, Rizavi HS, Roberts RC et al Reduced activation and expression of ERK1/2 MAPK in the post-mortem brain of depressed suicide subjects. I Neurochem. 77,916–928 (2001).
- Fatemi SH, Earle JA, Stary JM, Lee S et al Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuromport 12,3257–3262(2001).
- Stewart RJ, Chen B, Dowlatshahi D et al Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain. Res. Bull 55,625–629 (2001).
- Drevets WC, Price JL, Simpson JR, Jr. et al Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386,824–827 (1997).
- Rajkowska G, Miguel-Hidalgo JJ, Wei J et al Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 45,1085–1098 (1999).
- Czeh B, Michaelis T, Watanabe T et al Stress-induced changes in cerebral metabolites, hippocampal volume and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl Acad. Sci. USA 98,12796–12801 (2001).
- Gage FH. Structural plasticity: cause, result, or correlate of depression. Biol. Bychiatry48, 713–714 (2000).
- Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3', 5' -monophosphate phosphodiesterase inhibitors. Neuropharmacology22, 267–272 (1983).
- •Classical paper proposing the use of PDE inhibitors as antidepressants.
- Horowski R, Sastre-Y-Hemandez M. Clinical effects of the neurotrophic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. CL117: Ther Res. 38,23-29 (1985).
- Saletu B, Anderer P, Fischho PK et al. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biol. Psychiatry32, 668–681 (1992).
- Kaldcar R, Raju RV, Rajput AH et al Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res. 749, 290–294 (1997).
- Malison R, Price LH, Nestler EJ et al. Efficacy of papaverine addition in treatment-refractory major depression. Arn. PTchiatry 154,579–580 (1997).
- Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J: Neurochem. 53,1644–1647 (1989).
- Roberson ED, English JD, Adams JP et al. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. j Neurosci. 19,4337–4348 (1999).
- Thome J, Sakai N, Shin KH et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. j Neurosci. 20, 4030–4036 (2000).
- •Experiments demonstrating that chronic treatment with antidepressants causes phosphorylation of CREB and initiation of CRE-mediated gene transcription.
- Chen AC, Shirayama Y, Shin IKH et al Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol. Psychiatry 49,753–762 (2001).
- Pliakas AM, Carlson RR, Neve RL et al Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. Neumsci. 21,7397–7403 (2001).
- Cowen PJ. A role for 5-HT in the action of antidepressant drugs. Pharmacol Ther. 46, 43–51 (1990).
- Frazer A. Noradrenaline involvement in antidepressant action. I Clin. Psychiatry 61 (Suppl. 10), 25–30 (2000).
- Ozawa H, Rasenick MM. Chronic electroconvulsive treatment augments coupling of the GTP-binding portein Gs to the catalytic moiety of adenyl cyclase in a manner similar to that seen with chronic antidepressant drugs. I Neurochem. 56, 330–338 (1991).
- Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. Neumsci. 16,2365–2372 (1996).
- Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Neurosci. 15,7539–7547 (1995).
- Asanuma M, Nishibayashi S, Iwata E et al. Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor. Brain Res. Mal Brain Res. 41,210–215 (1996).
- Tao X, Finkbeiner S, Arnold DB et al Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20,709–726 (1998).
- Thome J, Foley P, Riederer P Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. J. Neural. 7iansm. 105,85-100 (1998).
- Altar CA. Neurotrophins and depression. Trench Pharmacol Sc]. 20,59–61 (1999).
- Chen B, Dowlatshahi D, MacQueen GM et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Rychiatry 50,260–265 (2001).
- Janz R, Sudhof TC, Hammer RE et al. Essential roles in synaptic plasticity for synaptogyrin land synaptophysin I. Neumn 24,687–700 (1999).
- Karson CN, Mrak RE, Schluterman KO et al. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mal Psychiatry 4, 39–45 (1999).
- Eastwood SL, Cairns NJ, Harrison PJ. Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex. BE j PFchiatry176,236–242 (2000).
- Egawa T, Mishima K, Matsumoto Y et al Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn. Pharmacol 75,275–281 (1997).
- SkLair-Tavron L, Nestler EJ. Opposing effects of morphine and the neurotrophins, NT-3, NT-4 and BDNF, on locus coeruleus neurons in rotna Brain Res. 702, 117–125 (1995).
- Siuciak JA, Lewis DR, Wiegand SJ et al. Antidepressant-like effect of brain derived neurotrophic factor (BDNF). Pharmacol Biochem. Behav. 56, 131–137 (1996).
- •One of the first papers demonstrating antidepressant properties of BDNF, a potential target gene of the cAMP signal transduction cascade.
- Mamounas LA, Blue ME, Siuciak JA et al BDNF promotes the survival and sprouting of serotonergic axons in the rat brain. J. Neurosci. 15,7929–7939 (1995).
- Vaidya VA, Siuciak J, Du F et al. Mossy fiber sprouting and synaptic reorganization induced by chronic administration of electroconvulsive seizure: role of BDNF. Neuroscience 89, 157–166 (1999).
- •Experiments demonstrating the effects of antidepressant treatment on neural and synaptic plasticity.
- Eriksson P, Perfileva E, Bjork-Eriksson T et al Neurogenesis in the adult human hippocampus. Nature Merl 4,1313–1317 (1998).
- Malberg JE, Eisch AJ, Nestler EJ et al Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. j Neurosci. 20, 9104–9110 (2000).
- •First paper demonstrating that antidepressant treatment influences neurogenesis.
- Dowlatshahi D, MacQueen GM, Wang JF et al. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 352, 1754–1755 (1998).
- Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sc]. 15, 220–226 (1994).
- Wachtel H, Schneider HD. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 25,1119–1126 (1986).
- CY Donnel JM. Antidepressant-like effects of rolipram and other inhibitors of cyclic AMP phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol Exp. Ther. 264,1168–1178 (1993).